滚动资讯
CellA skin-hypothalamus axis couples heat stress and metabolic dysfunctionCellThe evolution of high-order genome architecture revealed from 1,000 speciesCellSomatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative statesCellPyruvate is a natural suppressor of interferon signaling by inducing STAT1 protein pyruvylationCellMechanism-guided identification of antidepressant G protein-coupled receptor drug targetsBDArea Softball: PRB gets 2 wins - Brainerd DispatchFierceBiotechWCG收购The Contract Network,旨在简化临床试验执行流程RecursionRecursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com CanadaRecursionRecursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock TitanRecursion[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan
Endpoints News 2025年12月1日

Belite Bio凭借三期临床试验成功,力争获得Stargardt病治疗的首个批准。

Belite Bio凭借三期临床试验成功,力争获得Stargardt病治疗的首个批准。

暂时没有全文,请查看原始来源。